Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07365462 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Name: Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia — clinical trial record (NCT07365462)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorNeurocrine Biosciences

Started2026-02-06

View on ClinicalTrials.gov ↗

Amendment history

2026-06-19

Study Status, Contacts/Locations v3

Study sites17→18

2026-05-18

Study Status, Contacts/Locations v2

Trial sites expanded: 6 → 17 locations

Start date2026-01-23→2026-02-06

2026-04-21

Study Status, Contacts/Locations v1

Recruitment opened

Trial sites expanded: 0 → 6 locations

Start dateestimated 2026-01→confirmed 2026-01-23

2026-01-22

Original filing

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Trial Details

NCT Number	NCT07365462
Lead Sponsor	Neurocrine Biosciences
Conditions	Tardive Dyskinesia
Enrollment	100 participants
Start Date	2026-02-06
Primary Completion	2027-02 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-23